Dr. Annette Von Drygalski, MD

Dr. Von Drygalski practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Von Drygalski's NPI, 1376607036, was assigned on December 20, 2006. Dr. Von Drygalski graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 1996. Dr. Von Drygalski holds California license A100681.

Dr. Von Drygalski's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Von Drygalski's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Von Drygalski is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Von Drygalski practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Von Drygalski's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Von Drygalski is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Von Drygalski's licenses on file in 2 states: California and Wisconsin.

Dmand AI lists breast cancer, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Von Drygalski treats.

CMS data shows 85 Medicare services from Dr. Von Drygalski across 4 procedure codes in 2024, for 62 Medicare patients. Medicare paid $10,884 for them.

CMS counts 62 Medicare patients who saw Dr. Von Drygalski in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 35% are also on Medicaid. Their average risk score is 3.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Von Drygalski's median patient age at 48, with 56% women.

In 2024, Dr. Von Drygalski wrote 21 Medicare Part D claims. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $5,736 in total drug cost. In 2023, CMS named 20 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Von Drygalski for performance year 2024, reported as part of a group. Dr. Von Drygalski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Von Drygalski as offering telehealth.

Dmand AI links 72 papers to Dr. Von Drygalski, published from 2010 to 2025. 2022 was the busiest year, with 8. The most frequent topics are Hemophilia A, Hemarthrosis and Factor VIII. Dr. Von Drygalski has published most often in Haemophilia. Dr. Von Drygalski's most frequent co-authors are Doris Voy Kan Quon, MD, Eric Y. Chang, MD and Rebecca Kruse-Jarres, MD.

Dmand AI links Dr. Von Drygalski to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Coagulation Protein Disorders, Hemophilia A and Hemophilia B. Open Payments lists research payments to Dr. Von Drygalski that name 2 trials.

CMS Open Payments shows 330 general payments to Dr. Von Drygalski from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Sanofi and Genzyme US Companies paid the most, $102,033. It also lists 21 research payments totaling $10,565 from 2020 to 2025, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Von Drygalski, most recently CMS Stage 1 EHR in 2013.

Dr. Von Drygalski graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 1996.

Dr. Von Drygalski is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.